Brad Watts, senior vice president at the U.S. Chamber of Commerce’s Global Innovation Policy Center (GIPC), oversees the center’s day-to-day operations. He also leads the development and implementation of the Chamber’s U.S. and global intellectual property (IP) agenda to foster a political, legal, and economic environment where innovators and creators can invest in the next big thing for the benefit of Americans and the world.
Watts previously served as the Republican chief counsel on the Senate Judiciary Committee Subcommittee on Intellectual Property. There he was responsible for planning and implementing Senator Thom Tillis’ (R-NC) and the Republican party’s legislative portfolio on all aspects of IP law.
In the 116th Congress, when Senator Tillis was chairman of the subcommittee, Watts served as majority chief counsel and staff director for the Senate Judiciary Committee Subcommittee on Intellectual Property. He was responsible for implementing the senator’s legislative and oversight agenda on all aspects of America’s innovation economy.
During Watts’ tenure as majority chief counsel, the subcommittee held 17 legislative and oversight hearings and multiple staff briefings on IP issues, ranging from the state of patent eligibility law in America to reforming the Digital Millennium Copyright Act of 1998. Under his leadership, the subcommittee passed the CASE Act, the Trademark Modernization Act, and the Protecting Lawful Streaming Act, three landmark bills that collectively represent the largest changes to IP law since the Leahy-Smith America Invents Act.
Earlier, Watts was chief immigration counsel to then-Senate Judiciary Committee Chairman Chuck Grassley (R-IA). He began his career with former Senator Jeff Sessions (R-AL) as a legislative counsel on the Subcommittee on Immigration and the National Interest, handling civil rights and civil liberties law, general tort law, bankruptcy, telecommunications, and IP issues for the senator.
Comfort Care or Hastened Death? Assisted Suicide and the Medicare Hospice Benefit
Alexander Raikin, Jeffrey A. Singer, Daniel E. Troy
Assisted suicide is a contested issue in American law and medicine, raising questions over individual...
From the Courthouse Steps: Hikma v. Amarin
Adam Mossoff, Wesley Weeks
In Hikma Pharmaceuticals USA v. Amarin Pharma, the Supreme Court unanimously held that, to plausibly allege induced...
Is the FDA Trying to Ban Direct-to-Consumer Drug Ads?
Paul Avelar, Jeff Stier, Dan Troy
The Trump Administration has been exploring new ways to tighten requirements for direct-to-consumer advertisements for...
Medicare's New Drug Price Mandate: Healthcare & Innovation Implications
Lisa Larrimore Ouellette, Adam Mossoff, Dan Troy, Brad Watts
On January 17, the Biden-Harris Administration added 15 new drugs, including Ozempic, to the list of...
Does President Trump Have the Authority to Pause and Modify the Medicare Drug Price Negotiation Program?
John Shu, Jeff Stier, Dan Troy
Since its inception, the Inflation Reduction Act’s (IRA) Medicare Drug Price Negotiation Program has been...
Admitting Expert Evidence Under Rule 702: By What Standard?
Kateland R. Jackson, Leah Lorber, Lee S. Mickus, David Wool
This webinar will host a debate over the pending amendments to Federal Rule of Evidence...
Admitting Expert Evidence Under Rule 702: By What Standard?
Kateland R. Jackson, Leah Lorber, Lee S. Mickus, David Wool
This webinar will host a debate over the pending amendments to Federal Rule of Evidence...
Admitting Expert Evidence Under Rule 702: By What Standard?
TeleforumIt Can Be Done Live: The Future of Our Health
Julie Allickson, Nathan Kaczmarek, Betsy McCaughey, Christina Sandefur, Joshua Sharfstein, Dan Troy
The creators of the award-winning documentary, They Say It Can't Be Done, in partnership with the...
Deep Dive Episode 136 – It Can Be Done Live: The Future of Our Health
Julie Allickson, Betsy McCaughey, Joshua Sharfstein, Dan Troy, Christina Sandefur
The creators of the award-winning documentary, They Say It Can’t Be Done, in partnership with...